Comparison of the clinical parameters and imaging findings between the non-MNV group and subsequent MNV group
| Total (n=176) | Non-MNV group (n=153) | Subsequent MNV group (n=23) | P value | |
| Age (years) | 52.1±10.4 | 51.3±10.2 | 57.2±10.7 | 0.015* |
| Sex (male/female) | 112/40 | 97/34 | 15/6 | 0.800† |
| Systemic steroid use, n (%) | 35/152 (23.0) | 32/131 (24.4) | 3/21 (14.3) | 0.409† |
| Smoking, n (%) | 70/152 (46.1) (unknown: 20) | 60/131 (45.8) (unknown: 19) | 10/21 (47.6) (unknown: 1) | 0.493† |
| Bilateral involvement, n (%) | 52/152 (34.2) | 46/131 (35.1) | 6/21 (28.6) | 0.557† |
| Chronic CSC, n (%) | 67 (38.1) | 54 (35.3) | 13 (56.5) | 0.051† |
| SE (diopters) | −0.67±1.97 | −0.76±2.00 | −0.11±1.72 | 0.124* |
| Initial BCVA, logMAR (Snellen) | 0.10±0.26 (20/25) | 0.09±0.26 (20/25) | 0.15±0.24 (20/28) | 0.120* |
| Central retinal thickness (μm) (range) | 359.32±134.42 (110–953) | 362.3±138.1 (110–953) | 339.4±107.4 (207–671) | 0.440* |
| Choroidal thickness (μm) (range) | 381.55±108.83 (145–729) | 381.3±108.5 (145–729) | 383.3±113.5 (177–630) | 0.870* |
| Leakage sites within the fovea on FA, n (%) | 15 (8.5) | 10 (6.5) | 5 (21.7) | 0.015† |
| Multiple leakage points (≥2) on FA, n (%) | 105 (59.7) | 91 (59.5) | 14 (60.9) | 0.899† |
| Intense fluorescein leakage on FA, n (%) | 74 (42.0) (unknown: 58) | 61 (39.9) (unknown: 54) | 13 (56.5) (unknown: 4) | 0.194† |
| CVH on late-phase ICGA, n (%) | 142 (80.7) (unknown: 11) | 123 (80.4) (unknown: 11) | 19 (82.6) | 0.360† |
Values are the mean±SD or n (%).
*Statistical analysis with the Mann-Whitney U test.
†Statistical analysis with Fisher’s exact test or Pearson’s χ2 test.
BCVA, best-corrected visual acuity; CSC, central serous chorioretinopathy; CVH, choroidal vascular hyperpermeability; FA, fluorescein angiography; ICGA, indocyanine green angiography; logMAR, logarithm of the minimum angle of resolution; MNV, macular neovascularisation; SE, spherical equivalent.